Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -31.15% is 33% above its 5-year average of -46.24%, near the high end of its 5-year range (-85.81%–-20.25%).
59.86% above its 12-month average of -77.61%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -7.68%.
RETURN ON ASSETS (ROA)
-31.15%
RETURN ON ASSETS (ROA) AVG TTM
-77.61%
RETURN ON ASSETS (ROA) AVG 3Y
-57.20%
RETURN ON ASSETS (ROA) AVG 5Y
-46.24%
RETURN ON ASSETS (ROA) AVG 10Y
-41.21%
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+59.86%
CURRENT VS 3Y AVG
+45.54%
CURRENT VS 5Y AVG
+32.63%
CURRENT VS 10Y AVG
+24.41%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-26.34%
median of 496 covered companies
CURRENT VS SECTOR MEDIAN
-18.24%
vs the sector median at left
Editas Medicine, Inc.
Market Cap
$428.16M
Return on Assets (ROA)
-31.15%
TTM Avg
-77.61%
3Y Avg
-57.20%
5Y Avg
-46.24%
Market Cap
$416.68M
Return on Assets (ROA)
-41.58%
TTM Avg
-23.89%
3Y Avg
-13.16%
5Y Avg
-19.94%
Market Cap
$415.93M
Return on Assets (ROA)
-30.75%
TTM Avg
-34.79%
3Y Avg
-68.11%
5Y Avg
-68.11%
Market Cap
$410.54M
Return on Assets (ROA)
-71.16%
TTM Avg
-43.23%
3Y Avg
-31.68%
5Y Avg
-18.72%
Market Cap
$447.43M
Return on Assets (ROA)
-35.10%
TTM Avg
-26.63%
3Y Avg
-37.28%
5Y Avg
-39.51%
Market Cap
$408.21M
Return on Assets (ROA)
-41.33%
TTM Avg
-54.52%
3Y Avg
-54.52%
5Y Avg
-54.52%
Market Cap
$406.47M
Return on Assets (ROA)
-23.05%
TTM Avg
-30.00%
3Y Avg
-27.77%
5Y Avg
-27.77%
Market Cap
$450.64M
Return on Assets (ROA)
-0.01%
TTM Avg
-18.05%
3Y Avg
-43.07%
5Y Avg
-43.70%
Market Cap
$453.70M
Return on Assets (ROA)
-83.42%
TTM Avg
-53.06%
3Y Avg
-45.42%
5Y Avg
-42.54%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Editas Medicine, Inc. (EDIT) | $428.16M | -31.15% | -77.61% | -57.20% | -46.24% |
| Arcturus Therapeutics Holdings Inc. (ARCT)vs › | $416.68M | -41.58% | -23.89% | -13.16% | -19.94% |
| Carlsmed, Inc. (CARL)vs › | $415.93M | -30.75% | -34.79% | -68.11% | -68.11% |
| Atea Pharmaceuticals, Inc. (AVIR)vs › | $410.54M | -71.16% | -43.23% | -31.68% | -18.72% |
| Capricor Therapeutics, Inc. (CAPR)vs › | $447.43M | -35.10% | -26.63% | -37.28% | -39.51% |
| Eikon Therapeutics, Inc. Common Stock (EIKN)vs › | $408.21M | -41.33% | -54.52% | -54.52% | -54.52% |
| Shoulder Innovations, Inc. (SI)vs › | $406.47M | -23.05% | -30.00% | -27.77% | -27.77% |
| Assembly Biosciences, Inc. (ASMB)vs › | $450.64M | -0.01% | -18.05% | -43.07% | -43.70% |
| DiaMedica Therapeutics Inc. (DMAC)vs › | $453.70M | -83.42% | -53.06% | -45.42% | -42.54% |
| Kamada Ltd. (KMDA)vs › | $461.55M | 5.81% | 4.61% | 2.71% | 3.04% |
ROA
-31.1%
ROE
-70.2%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -85.81% |
| 2024-12-31 | -69.41% |
| 2023-12-31 | -30.70% |
| 2022-12-31 | -42.86% |
| 2021-12-31 | -28.41% |
| 2020-12-31 | -20.25% |
| 2019-12-31 | -26.28% |
| 2018-12-31 | -26.16% |
| 2017-12-31 | -32.24% |
| 2016-12-31 | -42.40% |
| 2015-12-31 | -48.81% |
| 2014-12-31 | -112.28% |
| 2013-12-31 | -215.60% |
